Literature DB >> 8849256

Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains.

E Azoulay-Dupuis1, P Moine, J P Bedos, V Rieux, E Vallee.   

Abstract

We used a mouse model of pneumococcal pneumonia to assess the bactericidal effect of increasing doses of amoxicillin (AMX) against clinical strains with various susceptibilities to penicillin. Twelve strains that exhibited similar virulence in mice were selected. Three were penicillin susceptible (PS) (penicillin and AMX MICs = 0.01 to 0.03 microgram/ml), three were intermediately resistant (PIR) (penicillin and AMX MICs = 0.5 to 1 microgram/ml), and six were penicillin resistant (PR) (penicillin and AMX MICs = 1 to 8 micrograms/ml). Leukopenic Swiss mice were infected intratracheally with 10(7) CFU of each strain. Treatment was initiated 3 h after infection and consisted of a single subcutaneous injection of AMX at doses ranging from 2.5 to 10 mg/kg (PS strains), 5 to 100 (PIR strains), and 25 to 3,000 (PR strains). Bacterial killing kinetics were recorded in the lungs over 9 h. The maximal log CFU reduction (Emax) was observed 3 h postinjection. The relation between Emax and log10(dose/MIC) showed two populations. With seven strains (the three PS, the three PIR, and one of the six PR [MICs, penicillin/AMX = 4/1]) a good correlation was observed between Emax and log10(dose/MIC) (r = 0.772; P < 0.02). A bactericidal effect equal to 3.5 log10 CFU was observed at a log10(dose/MIC) = 2. At this ratio, with the five other PR strains, Emax varied from 0.4 to 1.6 log10 CFU. In brain heart infusion medium containing AMX at 50 times the relevant MIC, these five PR strains were tolerant in vitro. Treatment failure with AMX was found in vivo, with tolerant, highly resistant strains.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849256      PMCID: PMC163235     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms.

Authors:  P Moreillon; Z Markiewicz; S Nachman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

2.  Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae.

Authors:  D E Briles; M J Crain; B M Gray; C Forman; J Yother
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

Review 3.  Antibiotic tolerance among clinical isolates of bacteria.

Authors:  E Tuomanen; D T Durack; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

4.  Calcium regulation of growth and differentiation in Streptococcus pneumoniae.

Authors:  M C Trombe; C Clavé; J M Manias
Journal:  J Gen Microbiol       Date:  1992-01

5.  Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae.

Authors:  H H Liu; A Tomasz
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

6.  [Relationship between virulence and resistance to antibiotics in pneumococci. Contribution of experimental data obtained in an animal model].

Authors:  J P Bédos; O Rolin; D H Bouanchaud; J J Pocidalo
Journal:  Pathol Biol (Paris)       Date:  1991-12

7.  Isolation of transformation-deficient Streptococcus pneumoniae mutants defective in control of competence, using insertion-duplication mutagenesis with the erythromycin resistance determinant of pAM beta 1.

Authors:  D A Morrison; M C Trombe; M K Hayden; G A Waszak; J D Chen
Journal:  J Bacteriol       Date:  1984-09       Impact factor: 3.490

8.  Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.

Authors:  E Azoulay-Dupuis; J P Bedos; E Vallée; D J Hardy; R N Swanson; J J Pocidalo
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

9.  In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  P Moine; E Vallée; E Azoulay-Dupuis; P Bourget; J P Bédos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Penicillin resistance and defective lysis in clinical isolates of pneumococci: evidence for two kinds of antibiotic pressure operating in the clinical environment.

Authors:  P Moreillon; A Tomasz
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

View more
  14 in total

1.  Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice.

Authors:  E Azoulay-Dupuis; V Rieux; M Muffat-Joly; J P Bédos; E Vallée; C Rivier; R Isturiz; C Carbon; P Moine
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  J P Bédos; V Rieux; J Bauchet; M Muffat-Joly; C Carbon; E Azoulay-Dupuis
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.

Authors:  Matilde Gracia; Carmina Martínez-Marín; Lorena Huelves; Maria J Giménez; Lorenzo Aguilar; Antonio Carcas; Carmen Ponte; Francisco Soriano
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

5.  Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  C Darras-Joly; J P Bédos; C Sauve; P Moine; E Vallée; C Carbon; E Azoulay-Dupuis
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

7.  Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis.

Authors:  I Lutsar; A Ahmed; I R Friedland; M Trujillo; L Wubbel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  Penicillin pharmacodynamics in four experimental pneumococcal infection models.

Authors:  H Erlendsdottir; J D Knudsen; I Odenholt; O Cars; F Espersen; N Frimodt-Møller; K Fuursted; K G Kristinsson; S Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

9.  Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model.

Authors:  I Gustafsson; E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

10.  Multicentre study of the molecular epidemiology, serotypes and antimicrobial susceptibility patterns of invasive Streptococcus pneumoniae invasive isolated from children in the Ille de France area.

Authors:  J-W Decousser; P Ovetchkine; A Collignon; C Chaplain; E Estrangin; A Fremaux; P Reinert; P Foucaud; J-C Ghnassia; R Cohen; J Gaudelus; P-Y Allouch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-12-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.